期刊
INTERNATIONAL REVIEWS OF IMMUNOLOGY
卷 28, 期 1-2, 页码 49-68出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/08830180802495605
关键词
vaccine development; HIV; multi-envelope; DNA-vaccinia virus-protein
类别
资金
- NIH NIAID [P01-AI45142]
- NIH NCI [P30-CA21765]
- Federated Department Stores
- Mitchell Fund
- Pendleton Fund, the Pioneer Fund and the American Lebanese Syrian-Associated Charities (ALSAC)
- NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI045142] Funding Source: NIH RePORTER
The human immune system has evolved to recognize antigenic diversity, a strength that has been harnessed by vaccine developers to combat numerous pathogens (e.g., pneumococcus, influenza virus, rotavirus). In each case, vaccine cocktails were formulated to include antigenic variants of the target. To combat HIV-1 diversity, we assembled a cocktail vaccine comprising dozens of envelopes, delivered as recombinant DNA, vaccinia virus, and protein for testing in a clinical trial. One vaccinee has now completed vaccinations with no serious adverse events. Preliminary analyses demonstrate early proof-of-principle that a multi-envelope vaccine can elicit neutralizing antibody responses toward heterologous HIV-1 in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据